JP7568651B2 - ブルトン型チロシンキナーゼ阻害薬を用いて慢性自発性蕁麻疹を治療する方法 - Google Patents

ブルトン型チロシンキナーゼ阻害薬を用いて慢性自発性蕁麻疹を治療する方法 Download PDF

Info

Publication number
JP7568651B2
JP7568651B2 JP2021568760A JP2021568760A JP7568651B2 JP 7568651 B2 JP7568651 B2 JP 7568651B2 JP 2021568760 A JP2021568760 A JP 2021568760A JP 2021568760 A JP2021568760 A JP 2021568760A JP 7568651 B2 JP7568651 B2 JP 7568651B2
Authority
JP
Japan
Prior art keywords
compound
formula
treatment
csu
urticaria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021568760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533981A5 (https=
JP2022533981A (ja
Inventor
バッタチャリア，スヴィック
ビエス，ブルーノ
カバンスキー，マチェイ
チェンニ，ブルーノ
バック，ステファン デ
カウル，マーティン
キニカー，アルビンド
ラディヴォイェヴィチ，アンドリヤナ
セベリン，トーマス
ストリム，ジュリアン
ガラミ，アレッサンドラ ヴィタリティ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2022533981A publication Critical patent/JP2022533981A/ja
Publication of JP2022533981A5 publication Critical patent/JP2022533981A5/ja
Priority to JP2024139784A priority Critical patent/JP2024178168A/ja
Application granted granted Critical
Publication of JP7568651B2 publication Critical patent/JP7568651B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021568760A 2019-05-23 2020-05-20 ブルトン型チロシンキナーゼ阻害薬を用いて慢性自発性蕁麻疹を治療する方法 Active JP7568651B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024139784A JP2024178168A (ja) 2019-05-23 2024-08-21 ブルトン型チロシンキナーゼ阻害薬を用いて慢性自発性蕁麻疹を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962851996P 2019-05-23 2019-05-23
US62/851,996 2019-05-23
PCT/IB2020/054755 WO2020234782A1 (en) 2019-05-23 2020-05-20 Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024139784A Division JP2024178168A (ja) 2019-05-23 2024-08-21 ブルトン型チロシンキナーゼ阻害薬を用いて慢性自発性蕁麻疹を治療する方法

Publications (3)

Publication Number Publication Date
JP2022533981A JP2022533981A (ja) 2022-07-27
JP2022533981A5 JP2022533981A5 (https=) 2023-05-26
JP7568651B2 true JP7568651B2 (ja) 2024-10-16

Family

ID=70918751

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568760A Active JP7568651B2 (ja) 2019-05-23 2020-05-20 ブルトン型チロシンキナーゼ阻害薬を用いて慢性自発性蕁麻疹を治療する方法
JP2024139784A Pending JP2024178168A (ja) 2019-05-23 2024-08-21 ブルトン型チロシンキナーゼ阻害薬を用いて慢性自発性蕁麻疹を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024139784A Pending JP2024178168A (ja) 2019-05-23 2024-08-21 ブルトン型チロシンキナーゼ阻害薬を用いて慢性自発性蕁麻疹を治療する方法

Country Status (22)

Country Link
US (2) US12419889B2 (https=)
EP (2) EP4599894A3 (https=)
JP (2) JP7568651B2 (https=)
KR (1) KR20220012281A (https=)
CN (1) CN113795255A (https=)
AU (2) AU2020280272B2 (https=)
BR (1) BR112021022602A2 (https=)
CA (1) CA3138081A1 (https=)
CL (1) CL2021003032A1 (https=)
DK (1) DK3972604T3 (https=)
ES (1) ES3039974T3 (https=)
FI (1) FI3972604T3 (https=)
HR (1) HRP20251001T1 (https=)
IL (1) IL286983B2 (https=)
LT (1) LT3972604T (https=)
MX (2) MX2021013942A (https=)
PL (1) PL3972604T3 (https=)
PT (1) PT3972604T (https=)
RS (1) RS67141B1 (https=)
SI (1) SI3972604T1 (https=)
TW (2) TW202537625A (https=)
WO (1) WO2020234782A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS67141B1 (sr) 2019-05-23 2025-09-30 Novartis Ag Inhibitor brutonove tirozin kinaze za upotrebu u lečenju hronične spontane urtikarije
JP7564347B2 (ja) 2021-09-03 2024-10-08 ノバルティス アーゲー 多発性硬化症を治療するためのｌｏｕ０６４
US20250032488A1 (en) 2021-12-14 2025-01-30 Novartis Ag Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
KR102834740B1 (ko) * 2023-04-10 2025-07-17 아주대학교산학협력단 Hsp10 또는 이의 항체를 유효성분으로 포함하는 만성 자발적 두드러기의 진단을 위한 바이오마커 조성물
WO2024235163A1 (zh) * 2023-05-12 2024-11-21 武汉人福创新药物研发中心有限公司 Btk抑制剂的用途和单剂量药物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016538313A (ja) 2013-11-29 2016-12-08 ノバルティス アーゲー 新規なアミノピリミジン誘導体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2705719C (en) 2007-09-14 2016-10-11 Janssen Pharmaceutica N.V. Thieno-and furo-pyrimidine modulators of the histamine h4 receptor
EP3092250A4 (en) 2014-01-08 2017-05-24 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
WO2016079669A1 (en) * 2014-11-19 2016-05-26 Novartis Ag Labeled amino pyrimidine derivatives
RS67141B1 (sr) 2019-05-23 2025-09-30 Novartis Ag Inhibitor brutonove tirozin kinaze za upotrebu u lečenju hronične spontane urtikarije

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016538313A (ja) 2013-11-29 2016-12-08 ノバルティス アーゲー 新規なアミノピリミジン誘導体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
James J. CRAWFORD et al.，"Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development"，Journal of Medicinal Chemistry，2018年02月19日，Vol. 61, No. 6，p.2227-2245，DOI: 10.1021/acs.jmedchem.7b01712
Sonali J. BRACKEN et al.，"Autoimmune Theories of Chronic Spontaneous Urticaria"，Frontiers in Immunology，2019年03月29日，Vol. 10，DOI: 10.3389/fimmu.2019.00627

Also Published As

Publication number Publication date
TWI868139B (zh) 2025-01-01
SI3972604T1 (sl) 2025-09-30
US20220184074A1 (en) 2022-06-16
RS67141B1 (sr) 2025-09-30
KR20220012281A (ko) 2022-02-03
MX2021013942A (es) 2022-01-04
EP3972604B1 (en) 2025-06-04
CN113795255A (zh) 2021-12-14
EP4599894A2 (en) 2025-08-13
PT3972604T (pt) 2025-08-26
TW202110450A (zh) 2021-03-16
AU2025252618A1 (en) 2025-11-06
AU2020280272A1 (en) 2021-11-18
EP3972604A1 (en) 2022-03-30
JP2024178168A (ja) 2024-12-24
AU2020280272B2 (en) 2025-07-24
EP4599894A3 (en) 2025-11-12
DK3972604T3 (da) 2025-09-15
BR112021022602A2 (pt) 2022-01-04
CA3138081A1 (en) 2020-11-26
MX2024014626A (es) 2025-01-09
CL2021003032A1 (es) 2022-09-09
IL286983B2 (en) 2026-01-01
JP2022533981A (ja) 2022-07-27
LT3972604T (lt) 2025-09-10
WO2020234782A1 (en) 2020-11-26
IL286983B1 (en) 2025-09-01
HRP20251001T1 (hr) 2025-10-24
IL286983A (en) 2021-12-01
ES3039974T3 (en) 2025-10-28
FI3972604T3 (fi) 2025-09-01
PL3972604T3 (pl) 2025-09-22
US12419889B2 (en) 2025-09-23
US20250375446A1 (en) 2025-12-11
TW202537625A (zh) 2025-10-01

Similar Documents

Publication Publication Date Title
JP7568651B2 (ja) ブルトン型チロシンキナーゼ阻害薬を用いて慢性自発性蕁麻疹を治療する方法
Limpongsanurak et al. Clinical practice guideline for diagnosis and management of urticaria
TWI857060B (zh) 使用布魯頓酪胺酸激酶抑制劑治療休格倫氏症候群之方法
TW202142229A (zh) 治療雷葛氏症候群之病患的方法
RU2818678C2 (ru) Способы лечения хронической спонтанной крапивницы с применением ингибитора тирозинкиназы брутона
RU2847617C2 (ru) Способы лечения хронической спонтанной крапивницы с применением ингибитора тирозинкиназы брутона
HK40126655A (en) Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor
HK40061328A (en) A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria
HK40061328B (en) A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria
HK40110203A (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
HK40061327B (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
HK40061327A (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
Tuchinda Thai Clinical Practice Guideline for Diagnosis and Management of Urticaria

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240821

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240821

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241003

R150 Certificate of patent or registration of utility model

Ref document number: 7568651

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150